-
In this issue: Drug shortages; metformin and cancer prevention; migraine prevention guidelines; and FDA actions.
-
To investigate the attitudes and practices of health care providers toward intrauterine device (IUD) use in nulliparous women, the authors performed a national survey of both office-based physicians and Title X health care providers from December 2009 to March 2010.
-
For years, clinicians have been trying to find ways to predict shoulder dystocia (SD), a complication that can have serious consequences for some infants and, on occasion, for the providers who delivered these babies.
-
The authors performed a randomized, single-blind trial of the effects of a paracervical block (PCB) or sham block on pain with cervical dilation and aspiration during first trimester abortion. Enrollment of subjects was stratified by gestational age (early: < 8 weeks, n = 60; late: 8-10 6/7 weeks, n = 60).
-
Your neighborhood pharmacy now offers checks for high blood pressure, cholesterol levels, and diabetes; testing for HIV might be the next addition in service.
-
The Food and Drug Administration (FDA) has cleared the OraQuick In-Home HIV Test for sale directly to consumers, which makes it the first and only rapid over-the-counter (OTC) HIV test approved in the United States.
-
In June 2012, the Centers for Disease Control and Prevention (CDC) released the U.S. Youth Risk Behavior Surveillance Summary (YRBS) for 2011.1 In the first paragraph, say the most significant finding from the report.
-
New research indicates that use of magnetic resonance imaging (MRI) is safe for use in women who rely on such contraceptive methods as intrauterine devices (IUDs) and implants, as well as in women who have tubal microimplants inserted during hysteroscopic sterilization.
-
Findings of a small study indicate that Shang Ring, a device in development, is safe and acceptable to men, which might aid in increasing access to voluntary adult male circumcision in areas at high risk of HIV.
-
The authors assessed the risk of venous thrombosis (vt) in current users of non-oral hormonal contraception using four national registries in Denmark.